10,600 Shares in Phreesia, Inc. $PHR Bought by Strs Ohio

Key Points

• Strs Ohio acquired a new stake in Phreesia, Inc. by purchasing 10,600 shares valued at approximately $271,000 during the first quarter.
• Analysts have a consensus rating of Buy on Phreesia, with target prices ranging from $33.00 to $38.00, suggesting considerable growth potential.
• Insider trading showed significant activity, with insiders selling over 125,000 shares in the last 90 days, indicating potential caution from company executives.

Strs Ohio bought a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 10,600 shares of the company's stock, valued at approximately $271,000.

A number of other large investors also recently modified their holdings of the business. KBC Group NV acquired a new position in Phreesia during the first quarter worth about $74,000. CWM LLC grew its stake in shares of Phreesia by 994.9% in the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after buying an additional 3,671 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after purchasing an additional 1,825 shares during the period. GAMMA Investing LLC boosted its position in shares of Phreesia by 10,605.7% in the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after acquiring an additional 5,621 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in Phreesia in the fourth quarter worth $163,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PHR shares. Mizuho initiated coverage on Phreesia in a research note on Wednesday, August 27th. They issued an "outperform" rating and a $36.00 target price for the company. Raymond James Financial set a $33.00 target price on Phreesia and gave the company an "outperform" rating in a research note on Friday, September 5th. Piper Sandler boosted their target price on Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a report on Friday, September 5th. Canaccord Genuity Group upped their price objective on Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a report on Friday, September 5th. Finally, KeyCorp raised their price objective on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company. According to MarketBeat, Phreesia presently has a consensus rating of "Buy" and an average price target of $34.08.

Insider Activity at Phreesia

In related news, insider David Linetsky sold 1,064 shares of the business's stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $23.50, for a total transaction of $25,004.00. Following the sale, the insider directly owned 173,888 shares in the company, valued at approximately $4,086,368. The trade was a 0.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Evan Roberts sold 3,761 shares of the company's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $87,556.08. Following the completion of the transaction, the insider owned 726,837 shares in the company, valued at $16,920,765.36. This represents a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 125,541 shares of company stock worth $3,661,812 in the last 90 days. 5.50% of the stock is owned by company insiders.

Phreesia Price Performance

Shares of NYSE:PHR opened at $23.66 on Thursday. The stock's fifty day simple moving average is $27.38 and its two-hundred day simple moving average is $26.36. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $32.76. The stock has a market cap of $1.42 billion, a PE ratio of -56.34 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business's revenue was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. As a group, analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.